KM Pharmaceuticals' Largest Shareholder Kang Il-mo Slightly Increases Stake to 39.62% via Share Pledge Extensions and Open Market Purchases
Chairman Kang Il-mo, as the largest shareholder of KM Pharmaceuticals, increased his stake by 1,200 shares to a total of 2,210,261 shares, raising his ownership from 39.60% to 39.62%.
The changes were driven by the extension of share collateral loan agreements with IBK Investment & Securities and the Industrial Bank of Korea, along with minor open market purchases. A total of 1,197,489 shares or 21.47% of outstanding shares are pledged as collateral.
Outstanding loan balances total approximately 4.04 billion KRW, with maturities extended to October and December 2026 respectively. This report is for management control purposes and involves no new share issuance or dilution.
[AI Summary]The slight increase in stake by the largest shareholder signals stability, but the high pledge ratio of 21.47% poses a risk of margin calls or forced liquidation in a declining market, warranting investor caution.